IDO1 and neoplasm: Furthermore, upregulation of IDO1 expression has been observed within the TME [12–14] and associated with inferior clinical outcomes in several tumor types, including melanoma [15–17], making IDO1 an attractive target for immunotherapy across a broad range of tumor types.